Phase IIb Study of STA-2 in Patients With Chronic Stable Angina

Mise à jour : Il y a 4 ans
Référence : NCT01239511

Femme et Homme

Extrait

The objective of this study is to evaluate the dose-response of three different dose levels of STA-2 (900 mg daily, 1800 mg daily and 2700 mg daily for 42 days) versus placebo in patients with chronic stable angina.


Critère d'inclusion

  • Chronic stable angina

Liens